H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Biogen (BIIB) to $228 from $194 and keeps a Buy rating on the shares. The firm sees “strong momentum” across Biogen’s growth products.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen: Undervalued Cash Flows and Growing Leqembi Franchise Support Raised Price Target and Buy Rating
- Biogen price target raised to $200 from $190 at Wells Fargo
- Biogen price target raised to $207 from $189 at BofA
- Biogen price target raised to $190 from $156 at Morgan Stanley
- Biogen price target raised to $215 from $185 at Citi